Genmab A/S Stock

Genmab A/S Stock-Based Compensation

The Stock-Based Compensation (SBC) of Genmab A/S (GMAB.CO) as of Aug 18, 2026 is 124.00 M USD. In the previous year, Stock-Based Compensation (SBC) was 104.57 M USD — a change of 18.58% (higher).

Stock-Based Compensation

124.00 MUSD

YoY

18.58%

Last updated:

Stock-Based Compensation (SBC) of Genmab A/S is 2026 124.00 M USD. Stock-Based Compensation (SBC) of Genmab A/S was 2025 104.57 M USD. It decreases by 18.58% higher compared to the previous year.
Access this data via the Eulerpool API

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Stock-Based Compensation (SBC) of Genmab A/S is 124.00 M USD in 2026.

Stock-Based Compensation (SBC) of Genmab A/S changed from 104.57 M USD to 124.00 M USD, representing a 18.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Genmab A/S historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Genmab A/S

All Key Metrics — Genmab A/S